Clinical Trial Update: A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis [Phase 1, Phase 2]

View source ↗

Summary

Kezar Life Sciences completed a Phase 1/2 study of the immunoproteasome inhibitor KZR-616 in systemic lupus erythematosus with and without lupus nephritis, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• KZR-616 (KZR-616)

Snippet

Sponsor: Kezar Life Sciences, Inc. | Conditions: Lupus Nephritis, Systemic Lupus Erythematosus | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-03-08